Furthermore, our in silico blood–brain barrier (BBB) permeability and molecular docking analysis suggested that antrocin is permeable to the BBB and exhibited robust ligand–receptor interactions with high binding affinities to CAMK4, TOMM70, and T1PRL, suggesting its potential as a new therapeutic agent for AD. This evidence concerns the gene CAMK4 and Alzheimer disease.